Introduction {#Sec1}
============

The treatment of neurological diseases is a huge problem. The search for appropriate treatments is under increased pressure as, on one hand, the results of drug candidates in clinical trials are very disappointing, while on the other hand an increase in the incidence of neurological diseases is occurring, probably due to an ageing society and life styles choices.

While having a significant effect in laboratory species, the failure of central nervous system (CNS) drug candidates in clinical phases may be caused by the drug candidate being given to the wrong subjects, administered at the wrong dose or schedule, or because of the lack of proper detection of the favorable effects of the CNS drug candidate. Thus, reasons for failure of CNS drug candidates can at least in part be found in inconclusive pharmacokinetic data, particularly regarding blood brain barrier (BBB) transport, inconclusive pharmacodynamic data, and the variability of the data due to the heterogenous nature of CNS pathologies in humans \[[@CR1]\]. Clearly, CNS drug research so far has not yielded solutions and the question is how to have the *right drug, at the right time, at the right concentration, at the right place?* To that end some main issues need to be addressed:How to obtain information on (what can be referred to as) the site of action in the CNS?How to appropriately diagnose neurological diseases, especially in an early stage?How to determine the effect of the drug on treatment of the disease?

To answer the first question, it is important to investigate particular the free CNS drug concentrations, These concentrations may serve as the best predictor of drug effects because CNS drug targets such as receptors, enzymes and transporters only interact with the free drug concentration \[[@CR2]--[@CR10]\]. Emphasis has therefore been put on obtaining reliable estimates of free drug concentrations in the brain extracellular (brain ECF) space that faces many of these targets \[[@CR11]\]. The most straightforward method to obtain information on free drug concentrations in human brain ECF is by cerebrospinal fluid (CSF) sampling. CSF is in close contact with brain ECF and therefore is expected to reflect the brain ECF composition. Human CSF sampling has been used (sparsely) for a long time as proof of CNS penetration, for CSF biomarker evaluation, and for pharmacokinetic-pharmacodynamic (PK-PD) modeling of CNS drugs.

However, today, questions abound on the utility of CSF sampling in neuroscience. It is therefore important to critically evaluate the use of CSF drug concentrations as source for information on brain ECF concentrations. The literature provides many, mostly older, studies in which CSF concentrations have been determined, and compared with (total) plasma concentrations, mostly at single time points, under assumed steady state conditions. With the later introduction of the microdialysis technique, information on the relationships between CSF concentrations and brain ECF concentrations became available. Such studies were typically performed in rodents because the brain microdialysis technique is invasive, though minimally \[[@CR12]\]. In humans, this technique has only been applied in extreme conditions such as brain trauma and brain surgery. For ethical reasons it has never been used in healthy volunteers (for details see Shannon et al. in this special issue).

This article will provide information on brain compartments from a physiological and anatomical perspective as basis for interpretation of drug transport into and within the brain. Studies will be presented in which CSF and brain ECF concentrations have been assessed and compared, followed by a systematic approach towards that leads to the possibility to use human CSF values to predict target site concentrations of CNS drugs \[[@CR13]\].

CNS compartments and drug transport processes {#Sec2}
---------------------------------------------

### Anatomy and physiology of the CNS {#Sec3}

The anatomy of the CNS is complex. It can grossly be divided into the following main compartments: brain extracellular fluid (brain ECF), brain parenchyma (brain cells), and the ventricular system. The ventricular system can be seen as a communicating network of cavities filled with CSF. It can be subdivided into the right and left lateral ventricles, the third ventricle, the cerebral aqueduct, the fourth ventricle, the cisterna magna, and the subarachnoid space (Fig. [1](#Fig1){ref-type="fig"}). In humans, the subarachnoid CSF in the lumbar region of the spinal cord (lumbar CSF) is of most interest with regard to CSF sampling, because of its accessability.Fig. 1Production, circulation and resorption of cerebrospinal fluid. The production of CSF mostly takes place in the choroid plexus of the ventricles. CSF circulates from the ventricles to the subarachnoid spaces, where resorption takes place via the arachnoid granulations and villi during circulation. From Kandel and Schwartz, Principles of Neural Science, Elsevier Science Publishing, NY, 1985, with permission

The exchange of substances from the brain ECF and CSF are regulated by the blood--brain barriers, i.e., the endothelial and epithelial interfaces that serve as barriers to blood. The endothelial cells of the brain capillaries that constitute the blood brain barrier (BBB) have tight junctions in the paracellular space that render this cell layer relatively impermeable to most hydrophilic molecules. In addition a plethora of transport mechanisms are available that control the exchange of compounds across the BBB \[[@CR14], [@CR15]\].

The choroid plexus and arachnoidal epithelial cells comprise the blood--CSF barrier (BCSFB). The BCSFB also restricts and highly controlsthe exchange of compounds. The BCSFB is comparable but quantitatively and qualitatively not equal to the BBB \[[@CR16]--[@CR18]\]. More permeable capillaries are found in the circum ventricular organs (CVOs), such as the subfornical organ in the third ventricle region \[[@CR19]\], than at the BBB.

CSF is continuously produced and eliminated. It provides a continuous circulation that acts more or less like a brain drainage system (Fig. [2](#Fig2){ref-type="fig"}). Under normal circumstances the human brain produces \~0.35 ml/min (500 ml/day). The total volume of human CSF is \~150 ml. This indicates that the CSF turnover is \~4 times/day \[[@CR19]\]. Although the exact locations of CSF production are still not clear there are known CSF production sites. The majority of CSF is formed in the choroid plexus of the lateral ventricles. Smaller amounts are formed by the choroid plexus of the third and fourth ventricles. The production is mediated by the filtration of plasma through fenestrated capillaries and by active transport of water and dissolved substances through the epithelial cells of the BCSFB. In addition, there are indications that drainage of the brain ECF contributes to CSF formation \[[@CR15]\]. Furthermore, it has been demonstrated that a substantial portion of subarachnoid CSF cycles through the brain interstitial space \[[@CR20], [@CR21]\]. Elimination of CSF takes place mostly via the granulations (kind of valves) of the arachnoid villi, where CSF flows into the blood. This process is driven by the hydrostatic pressure difference between the CSF and the cerebral veins \[[@CR22], [@CR23]\]. In addition, spinal venous reabsorption of CSF has been proven to exist \[[@CR24]\].Fig. 2Simplifed and schematic representation of the production, flow and elimination of brain fluids

In the rat these processes are similar although the particular physiological volumes and flow rates have different values. Table [1](#Tab1){ref-type="table"} shows the values for both rat and human, which is important in scaling by physiologically-based PK modeling \[[@CR25]\].Table 1Human and rat approximate values for brain physiological parametersParameterHuman valueRat valueCSF volume150 ml \[[@CR19]\]250 ul \[[@CR65]\]))CSF production0.35 ml/min \[[@CR19]\]2.2 ul/min \[[@CR66], [@CR67]\]CSF turnover4 times/day \[[@CR19]\]11 times/day \[[@CR19]\]Brain weight1400 g \[[@CR68]\]1.8 g (own observations)Brain ECF volume240 ml \[[@CR14]\]290 ul \[[@CR66], [@CR67]\]Brain ECF production (bulk flow)0.15--0.20 ml/min \[[@CR14], [@CR15], [@CR69]\]0.2--0.5 ul/min \[[@CR15], [@CR66]\]Cerebral blood flow700 ml/min \[[@CR70]\]1.1 ml/min \[[@CR71]\]

### Processes that govern local pharmacokinetics of the free drug in the CNS {#Sec4}

Drug transport into, within, and out of the brain is governed by the free drug concentrations in plasma, transport across the brain barriers, CSF turnover and ECF bulk flow, extra-intracellular exchange, brain tissue binding and brain drug metabolism (Fig. [3](#Fig3){ref-type="fig"}). These processes have been extensively addressed in previous publications \[[@CR11], [@CR16], [@CR26]--[@CR28]\]. It is important to note that transport across the blood--brain barriers may occur by simple diffusion, facilitated diffusion, vesicle transport, or active transport, or combinations of these, depending on the drug. All these processes occur concomitantly, and will influence each other's rate and extent, such that these interrelationships need to be considered in ultimately predicting CNS target site concentrations, and resulting drug effects \[[@CR2], [@CR29]\].Fig. 3Simplified and schematic representation passive and active transport processes, metabolism, and fluid flow, that all govern the concentration--time profile of the free drug at different sites in the CNS, and therewith CNS drug effects

As many important CNS targets currently identified are membrane bound receptors facing the brain ECF, the concentrations in this compartment are of high value in availability of the drug to interact with its CNS target. In order to have the *right drug at the right place at the right time in the right concentrations*, the drug properties and pharmacokinetic processes that govern drug concentrations at specific CNS sites, must be known, ideally with measurements included on target engagement and on drug effects.

What methods are available to obtain information on unbound brain pharmacokinetic data? {#Sec5}
=======================================================================================

For a long time, monitoring approaches have been searched for that could be used to predict human target site kinetics and (therewith) CNS effects. As it is the free drug that is available for target binding, in the early 1980s it was anticipated that CSF drug concentrations could serve as a biomarker for free brain target site concentrations (with no protein binding of drugs in CSF taking place at least under physiological conditions) \[[@CR30]\].

Single and repeated CSF sampling {#Sec6}
--------------------------------

The simplest way to study the entry of drugs into the CNS is to measure drug concentrations in the lumbar CSF collected by a single lumbar puncture during continuous intravenous infusion. While CSF may not necessarily be equal to or closely resembles CNS target site concentrations, this method provides information on the extent of drug distribution between plasma and lumbar CSF. This may be useful knowledge, but leaves out any information on time-dependency (rate) \[[@CR31]\]. Via a permanent cannula in the cisterna magna, it is possible to perform repeated (serial) CSF sampling in rats. Thus, the time-course of concentrations in CSF can be obtained in parallelly with CNS drug effects. This provides the possibility of within-subject cross-over designed studies \[[@CR32]\]. Also in humans sequential repeated CSF sampling is possible \[[@CR33]\]. By in repeated CSF sampling, however, the constant withdrawal of CSF may influence physiology. This is a concern and must be taken into account \[[@CR34]\].

Microdialysis {#Sec7}
-------------

Microdialysis is a technique that is based on the constant perfusion of a very small probe, with a tip that consists of a semipermeable membrane. Molecules small enough to pass this membrane will traverse the semipermeable membrane towards the lowest concentration according to the concentration gradient. When placed into a tissue, molecules from the extracellular space will enter the perfusate, which becomes the dialysate that can be collected outside of the subject, and can subsequently be analyzed on the compound of interest by an analytical technique of choice, to have information on the compound as a function of time in the dialysate. Dialysate concentrations reflect the true unbound PK in the extracellular fluid surrounding of the microdialysis tip, which can be estimated after appropriate correction for so called "in vivo recovery" \[[@CR35]--[@CR39]\].

To date no other technique is able to obtain such quantitative and time resolved information on the unbound drug of interest as by CSF sampling. However, while minimally invasive to the brain of rats \[[@CR12]\], the technique is not widely applicable to human brain. Even the smallest injury to the human brain made by choice should be avoided, if it were not for substantial motifs in benefiting the patient otherwise. Thus, microdialysis has been applied frequently in trauma patients. Monitoring concentrations of (e.g.) lactate and pyruvate as biological markers of brain tissue injury in traumatic brain can be very helpful in the judgement of the condition of the patient and to aid in treatment decisions, well before being able to observe and judge this on the basis of clinical assessments \[[@CR40]\]. Microdialysis in human brain can also be combined with neurosurgical procedures, for example before removal of epileptogenic brain tissue. In such settings microdialysis can also be used to measure brain penetration of drugs \[[@CR41]--[@CR46]\], and provides the possibility to determine brain pharmacokinetics in conjunction with resulting biochemical efficacy of therapeutic approaches \[[@CR40], [@CR47], [@CR48]\].

Because microdialysis, for obvious ethical reasons, cannot be applied as a technique to be used in humans for the purpose of drug development, human CSF is still considered the best possible fluid to obtain from humans that approximates unbound drug concentrations in brain ECF \[[@CR49]\]. The question remains how closely CSF concentrations reflect brain ECF concentrations in different locations in the brain, in diseases, and for different drugs.

Available data on CSF--ECF relationships {#Sec8}
----------------------------------------

With the introduction of microdialysis techniques, the possibility of making a direct comparison of CSF and brain ECF concentrations in animals became available. Also, intrabrain distribution aspects of drugs could be determined. Sawchuk's group at the University in Minnesota was the first to do so. In rats, zidovudine and stavudine concentration--time profiles were obtained in CSF and Brain ECF, and challenged by inhibition of active transport processes \[[@CR50]--[@CR52]\]. Shen et al. \[[@CR27]\] provided an extensive overview on CSF and brain ECF concentrations for drugs from many therapeutic classes with a wide spectrum in physico-chemical properties. Appending data of more recent studies, Table [2](#Tab2){ref-type="table"} presents CSF -brain ECF relationships for a broad set of drugs, including the methodology of assessment. These values have resulted from microdialysis to obtain brain ECF as well as CSF concentrations, CSF sampling for assessing CSF concentrations, as well as he brain slice method to obtain brain ECF concentrations. The brain slice method estimates brain ECF concentrations by determining total brain concentrations after drug administration, and to correct for the free fraction as obtained in brain slices after bathing the slice in a buffer solution containing the drug(s) of interest \[[@CR53], [@CR54]\].Table 2Drugs and their Kpuu, CSF and Kpuu, brain values obtained in animals (rats, sheep, rabbits, rhesus monkeys, and nonhuman primates) on the basis of steady state (SS) values, AUC values, continuous infusion (cont inf)CompoundSpeciesTimeKpuu, CSFKpuu, brainReference9-OH-RisperidoneRat6 h cont inf0,06840,0143\[[@CR61]\]AcetaminophenRatAUC (partial)0,31,2\[[@CR25]\]AlovudineRatSS0,40,16\[[@CR72]\]AntipyrineRat2 h cont inf0,990,708\[[@CR56]\]AtomoxetineRatSS1,70,7\[[@CR64]\]BaclofenRatPseudo SS0,0280,035\[[@CR73]\]BenzylpenicillinRat2 h cont inf0,01340,0264\[[@CR56]\]BuspironeRat2 h cont inf0,5580,612\[[@CR56]\]CaffeineRat2 h cont inf1,030,584\[[@CR56]\]CarbamazepineRat2 h cont inf0,5350,771\[[@CR56]\]CarbamazepineRat6 h cont inf0,1670,232\[[@CR61]\]CarboplatinNonhuman primateAUC0,050,05\[[@CR74]\]CefodizimeRatSpecific time0,020,22\[[@CR75]\]CeftazidimeRatSS0,0390,022\[[@CR76]\]CeftriaxoneRatSS0,710,8\[[@CR76]\]CephalexinRat2 h cont inf0,02250,016\[[@CR56]\]CimetidineRat2 h cont inf0,02110,00981\[[@CR56]\]CisplatinNonhuman primateAUC0,050,05\[[@CR74]\]CitalopramRat2 h cont inf0,6670,494\[[@CR56]\]CitalopramRat6 h cont inf0,50,559\[[@CR61]\]CP-615,003RatSS0,010,0014\[[@CR77]\]DaidzeinRat2 h cont inf0,1890,0667\[[@CR56]\]DantroleneRat2 h cont inf0,08380,0297\[[@CR56]\]DiazepamRat2 h cont inf0,8470,805\[[@CR56]\]DiphenylhydramineSheepSS (adults)3,43,4\[[@CR78]\]DiphenylhydramineSheepSS (30 d lambs)4,96,6\[[@CR78]\]DiphenylhydramineSheepSS (10 d lambs)5,66,6\[[@CR78]\]EAB515Rat15 h0,180,08\[[@CR51]\]FlavopiridolRat2 h cont inf0,2160,0525\[[@CR56]\]FleroxacinRat2 h cont inf0,2830,25\[[@CR56]\]FleroxacinRatSS0,420,15\[[@CR79]\]GanciclovirRat6 h cont inf0,06470,0711\[[@CR61]\]GenisteinRat2 h cont inf0,5890,181\[[@CR56]\]LamotrigineRatSS1,51\[[@CR62]\]LoperamideRat2 h cont inf0,03760,00886\[[@CR56]\]MetoclopramideRat6 h cont inf0,1690,235\[[@CR61]\]MidazolamRat2 h cont inf1,352,19\[[@CR56]\]MorphineRatAUC0,1970,51\[[@CR80]\]M6GRatAUC0,0290,56\[[@CR80]\]*N*-desmethylclozapineRat6 h cont inf0,01510,01\[[@CR61]\]NorfloxacinRatSS0,0330,034\[[@CR79]\]OfloxacinRatSS0,230,12\[[@CR79]\]OxaliplatinNonhuman primateAUC0,655,3\[[@CR74]\]PerfloxacinRat2 h cont inf0,3890,199\[[@CR56]\]PerfloxacinRatSS0,370,15\[[@CR79]\]PhenytoinRat2 h cont inf0,3960,447\[[@CR56]\]PhenytoinRatAUC0,20,85\[[@CR81]\]ProbenecidRatSS0,60,2\[[@CR82]\]QuinidineRat2 h cont inf0,09110,026\[[@CR56]\]QuinidineRat6 h cont inf0,09690,0459\[[@CR61]\]RisperidoneRat2 h cont inf0,1240,0787\[[@CR56]\]RisperidoneRat6 h cont inf0,09130,0422\[[@CR61]\]SalicylateRatSS0,50,1\[[@CR82]\]SDZ EAA 494RatAUC0,170,11\[[@CR83]\]SertralineRat2 h cont inf0,8321,85\[[@CR56]\]StavudineRatSS0,50,3\[[@CR84]\]StavudineRatSS0,60,6\[[@CR52]\]SulpirideRat2 h cont inf0,04990,0219\[[@CR56]\]ThiopentalRat2 h cont inf0,5990,911\[[@CR56]\]ThiopentalRat6 h cont inf0,06630,0663\[[@CR61]\]TiagabineRatAUC0,0110,011\[[@CR85]\]VerapamilRat2 h cont inf0,3330,0786\[[@CR56]\]YM992RatSS1,71,4\[[@CR86]\]ZidovudinRabbitAUC0,170,08\[[@CR50]\]ZidovudinRabbitSS0,290,19\[[@CR87]\]ZidovudinRhesus MonkeySS0,270,15\[[@CR88]\]Zidovudin + probenecidRabbitAUC0,190,1\[[@CR50]\]ZolpidemRat2 h cont inf0,4750,447\[[@CR56]\]

As a measure for the extent of distribution, the "Kpuu" value is used and defined as the ratio of the unbound tissue (brain) concentration over the unbound plasma concentration, at equilibrium. Figure [4](#Fig4){ref-type="fig"} shows the relationship of observed data on Kpuu, CSF and Kpuu, brain, obtained from the data presented in Table [2](#Tab2){ref-type="table"} for healthy rats, as well as the relationship between rat and human Kpuu, CSF values \[[@CR55]\]. These figures clearly indicate that CSF concentrations in the healthy rat correlate rather well with brain ECF concentrations although there is a trend for the Kpuu, CSF values to be slightly larger than the Kpuu, brain values. This may, at least in part, be due to more efficient drug elimination from brain ECF by active efflux mechanisms at the BBB, like mediated by *P*-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) \[[@CR56]\].Fig. 4**a** Relationship between the CSF/plasma unbound (Kpuu, CSF) and brain ECF/plasma unbound ratios (Kpuu, brain) obtained at presumed steady state conditions or by AUC comparisons) in healthy animals for data depicted in Table [2](#Tab2){ref-type="table"}, and **b** for rat versus human Kpuu, CSF values (redrawn from Friden et al. (2009)). Note in **b** the *open circle* representing a value for moxalactam obtained from a healthy volunteer, and on the same horizontal line the *half filled circle* representing a value for moxalactam obtained from a patient with bacterial meningitis

The relationship between rat and human Kpuu, CSF is more variable. There is a trend for human Kpuu, CSF to be larger than rat Kpuu, CSF. One reason for this may be that human CSF most probably has been obtained under disease conditions. These conditions might have influenced blood--brain transport, blood flow and/or metabolism, therewith affecting the Kpuu values \[[@CR43], [@CR57], [@CR58]\]. For moxalactam there is some proof for this as one of the two human values for Kpuu, CSF has been obtained under "normal" conditions, and the other under "diseased" conditions (Fig. [4](#Fig4){ref-type="fig"}b), \[[@CR55]\]. Here, the "diseased" Kpuu, CSF was larger than the "healthy" Kpuu, CSF value. It may may very well be that this Kpuu, CSF has reflected the corresponding Kpuu, brain in humans, as is known for moxifloxacin in bacterial meningitis \[[@CR59]\]. In addition to the possibility of disease influencing Kpuu, CSF, other factors such as the site of CSF withdrawal and age of the patients may play a role \[[@CR58], [@CR60]\].

There is one example of a study in which brain ECF, brain tissue, CSF, and serum concentrations of antiepileptic drugs were obtained intraoperatively from patients with intractable epilepsy \[[@CR45]\], and compared. Specifically, carbamazepine (CMZ), 10-hydroxy-carbazepine (10-OH-CZ, the active metabolite of oxcarbazepine), lamotrigine (LTG), and levetiracetam (LEV) were investigated. Overall it was found that CSF concentrations were significantly higher than corresponding brain ECF concentrations. This ratio was \~2.5 for CMZ, \~3.5 for both 10-OH-CZ and LEV, and \~4.0 for LMT. This is extremely valuable information, as this relationship has been shown for the first time in human. For rats, under control conditions, the CSF/brain ECF ratio for CMZ was \~0.7 for two independent studies \[[@CR56], [@CR61]\] and \~1.5 for LMT \[[@CR62]\].

Overall, it can be concluded that CSF drug concentrations in rat, under controlled conditions, can give a rather good indication, but not a reliable prediction of brain ECF concentrations \[[@CR3]\]. When it comes to humans, the conditions of the human individuals are highly variable, such that the relationship between rat CSF and human CSF concentrations gets more scattered. But, apart from the only study by Rambeck et al. \[[@CR45]\], information about the relation between human CSF and human brain ECF concentrations is still unavailable.

As human CSF is the only fluid that can be obtained from human CNS, it is for that reason highly valuable and new approaches to derive more information from human CSF data are needed. To that end, much more mechanistic insight is needed on the processes that govern intrabrain distribution of drugs. This can be obtained from animal studies, and combined with data on the relationship between CSF and brain ECF concentrations from those exceptional cases where microdialysis is allowed to be used in individual patients.

Recently, Westerhout et al. \[[@CR25]\] performed a series of studies using a multiple microdialysis probe design in the rat for measuring brain ECF concentrations and concomitant CSF concentrations in the lateral ventricle and cisterna magna (Fig. [5](#Fig5){ref-type="fig"}). Acetaminophen was the first paradigm compound, representing a moderately lipophilic drug for which only passive transport across the blood--brain barriers and within the brain occurs. The data obtained were used to build an advanced semi-physiological mathematical model of the brain, in which literature values of rat brain physiology were incorporated (Fig. [6](#Fig6){ref-type="fig"}), This model was able to describe the rat pharmacokinetic data in the different brain compartments adequately. Interestingly, after scaling the physiological parameters to the human values, this model was able to predict available literature data on human lumbar CSF concentrations \[[@CR63]\]. This gave much confidence in the model structure and values, as well as in the prediction of brain ECF acetaminophen concentrations in human (Fig. [7](#Fig7){ref-type="fig"}). Recently, studies have been performed with quinidine, as a moderately lipophilic Pgp substrate. The Pgp inhibitor tariquidar was used to learn more about the impact of specifically Pgp functionality \[REF, manuscript under revision, just accepted for publication in JPKPD if revised\]. Furthermore, studies have been performed for methotrexate, as a hydrophilic Mrp substrate, in which probenecid was used to study the impact of MRP functionalities on brain distribution (yet unpublished data).Fig. 5Using the parallel microdialysis probe design, pharmacokinetics of drugs at multiple sites in the brain can be assessed in individual animals, allowing direct comparison of concentration--time profiles of the free drug at these sitesFig. 6Physiologically based pharmacokinetic model of brain distribution, as derived for acetaminophen in the rat in which *plasma*, *brain ECF*, *CSF* in lateral ventricle, and *CSF* in cistern magna were assessed in parallelFig. 7Successfull prediction of unbound human plasma and lumbal CSF (subarachnoid space, SAS), obtained by Bannwarth et al. \[[@CR60]\], by the preclinically derived PBPK model for acetaminophen, and prediction of human brain ECF pharmacokinetics (Westerhout et al. \[[@CR25]\])

Conclusions and perspectives {#Sec9}
============================

The development of drugs for CNS disorders has encountered high failure rates. In part this has been due to the sole focus on BBB permeability of drugs, without taking into account all other processes that determine drug concentrations at the target site. Moreover, conditional dependence of these processes has typically been neglected. The difficulty therefore relies in how to predict human brain target site concentrations, which in many cases most closely relates to brain ECF concentrations. In human, the only fluid that can be obtained is CSF.

So far it has been shown that in animals, under presumed steady state conditions, CSF concentrations tend to overestimate brain ECF concentrations. No clear relationship to the physicochemical properties of the drug could be identified \[[@CR27]\]. However, active efflux transport at the brain ECF level for Pgp substrates seems to contribute to this phenomenon \[[@CR16], [@CR55], [@CR56]\]. When comparing rat CFS concentrations with human CSF concentrations, human CSF concentrations tend to be higher and display much more variability. It should also be considered that the comparison here is made between *healthy* rats and humans that most probably beared a (CNS) disease that invalidates any direct comparison with healthy rats.

In order to be able to more accurately predict human brain ECF concentrations, our understanding of CNS complexity in terms of intrabrain pharmacokinetic relationships, brain distribution, and the influence of CNS disorders needs to increase. This could be achieved by performing more studies to obtain pharmacokinetic data in parallel from brain ECF and CSF compartments in animals, and building a generic PBPK model of brain distribution \[[@CR11], [@CR25], [@CR29], [@CR64]\]. Such a model should include influences of drug properties, fluid flows, transporter functionalities and the influence of different disease conditions. Finally, the free concentrations in different sites of the brain should be connected to measures of target site engagement and CNS effects to learn from best predictor concentrations for particular targets.

CSF fluid is the only accessible fluid in the human CNS, and for that reason is of high value. If the rat PBPK model is scaled to humans and the model successfully predicts human CSF concentration in the compartment where the information was obtained from, this increases our trust in the prediction of brain ECF concentrations using the model \[25, 89\]. The model could also be refined by including more "generating data---model prediction---model validation---confirm or adjust" cycles.

In summary, human CSF data can be of high value if we have the knowledge that enables us to extrapolate the CSF concentrations to brain target site concentrations, in order to predict the CNS effect in individual human conditions.
